AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33346740 — intervention group
Group type: EXPERIMENTAL
Intervention: Word2Vec convolutional neural network (CNN) MBR algorithms
Number of subjects: 14075
Study 33346740 — intervention group
Group type: EXPERIMENTAL
Intervention: Word2Vec CNN MBR combined with rule-based reasoning (RBR)
Number of subjects: 14075
Study 33346991 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD support
Number of subjects: 43
Study 33346991 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD patients with thromboembolic events (TEs)
Number of subjects: 43
Study 33346991 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD implantation
Number of subjects: 43
Study 33347326 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 0
Study 33347326 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 0
Study 33347327 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details not available
Number of subjects: 0
Study 33347373 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilation velocity
Number of subjects: 0
Study 33347495 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment
Number of subjects: 493
Study 33347618 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1132
Study 33347715 — intervention group
Group type: EXPERIMENTAL
Intervention: 225Ac-labeled CD33-targeting antibody
Number of subjects: 0
Study 33347715 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax
Number of subjects: 0
Study 33347814 — intervention group
Group type: EXPERIMENTAL
Intervention: PARP inhibitors
Number of subjects: 9000
Study 33347814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9000
Study 33347946 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% silver diamine fluoride (SDF) applied topically for 2 minutes, repeated every 6 months
Number of subjects: 62
Study 33348423 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological treatment (modifying environmental stimulation)
Number of subjects: 353
Study 33348423 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological treatment (feeding practices)
Number of subjects: 353
Study 33348423 — intervention group
Group type: COMPARATOR
Intervention: Non-pharmacological treatment (support of the maternal-infant dyad)
Number of subjects: 353
Study 33348425 — intervention group
Group type: EXPERIMENTAL
Intervention: Nolix device
Number of subjects: 26
Study 33348999 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins (specific type, dosage, and duration not available)
Number of subjects: 0
Study 33348999 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific treatment or placebo not available)
Number of subjects: 0
Study 33349123 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR T cell therapy combined with oncolytic viruses (OVs)
Number of subjects: 0
Study 33349123 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33350030 — intervention group
Group type: EXPERIMENTAL
Intervention: SomBP1 (SOMNOtouch NIBP device)
Number of subjects: 51
Study 33350030 — intervention group
Group type: EXPERIMENTAL
Intervention: SomBP2 (SOMNOtouch NIBP device)
Number of subjects: 51
Study 33350030 — intervention group
Group type: COMPARATOR
Intervention: OscBP (validated oscillometric device)
Number of subjects: 51
Study 33350181 — intervention group
Group type: EXPERIMENTAL
Intervention: Silica-calcium phosphate composite (SCPC) granules
Number of subjects: 10
Study 33350181 — intervention group
Group type: COMPARATOR
Intervention: Control ungrafted sockets
Number of subjects: 10
Study 33350618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 20% albumin at 3 mL/kg over 30 minutes
Number of subjects: 15
Study 33350943 — intervention group
Group type: EXPERIMENTAL
Intervention: Client food bags HEI-2010 scores
Number of subjects: 575
Study 33350943 — intervention group
Group type: COMPARATOR
Intervention: Pantry inventory HEI-2010 scores
Number of subjects: 575
Study 33350943 — intervention group
Group type: EXPERIMENTAL
Intervention: Client food bag whole-grains scores
Number of subjects: 575
Study 33351103 — intervention group
Group type: EXPERIMENTAL
Intervention: α-1-antitrypsin (AAT) treatment
Number of subjects: 30
Study 33351103 — intervention group
Group type: COMPARATOR
Intervention: MAGIC control group
Number of subjects: 30
Study 33351137 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ENO1 IgG2
Number of subjects: 221
Study 33351137 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H2A IgG2
Number of subjects: 221
Study 33351137 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-ANXA1 IgG2
Number of subjects: 221
Study 33351137 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-dsDNA IgG2
Number of subjects: 221
Study 33351137 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria
Number of subjects: 221
Study 33351179 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 0
Study 33351179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33351205 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up samples of testosterone concentrations
Number of subjects: 400
Study 33351205 — intervention group
Group type: COMPARATOR
Intervention: Baseline samples of testosterone concentrations
Number of subjects: 400
Study 33351205 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) measurements
Number of subjects: 400
Study 33351775 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-use smell and taste test kit for daily self-assessments over 28 days
Number of subjects: 69
Study 33351775 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized smell and taste test
Number of subjects: 69
Study 33351775 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires to record recent changes in smell and taste ability
Number of subjects: 69
Study 33352123 — intervention group
Group type: EXPERIMENTAL
Intervention: Scene construction
Number of subjects: 0
Study 33352123 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization
Number of subjects: 0
Study 33352123 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processes
Number of subjects: 0
Study 33352201 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (60 mg) + Gemcitabine (1000 mg/m²)
Number of subjects: 28
Study 33352201 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib + Gemcitabine
Number of subjects: 28
Study 33352296 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral therapy
Number of subjects: 85
Study 33352296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 85
Study 33352296 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 85
Study 33353741 — intervention group
Group type: EXPERIMENTAL
Intervention: Baveno VI criteria
Number of subjects: 0
Study 33353741 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33354492 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training
Number of subjects: 78
Study 33354492 — intervention group
Group type: COMPARATOR
Intervention: In-person training
Number of subjects: 78
Study 33354492 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 78
Study 33354776 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin
Number of subjects: 0
Study 33354776 — intervention group
Group type: EXPERIMENTAL
Intervention: Icaritin in combination with checkpoint antibodies (α-PD-1)
Number of subjects: 0
Study 33354862 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 409306 50 mg twice daily for 52 weeks
Number of subjects: 300
Study 33354862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 33355229 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCR-177
Number of subjects: 0
Study 33355229 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 33355235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health readiness assessment via a 30-item questionnaire
Number of subjects: 949
Study 33355235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health proficiency by age group
Number of subjects: 949
Study 33355235 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health proficiency by ethnicity and education
Number of subjects: 949
Study 33355235 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status and mobile health proficiency
Number of subjects: 949
Study 33355235 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dialysis and mobile health proficiency
Number of subjects: 949
Study 33355238 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4166 900 mg i.v. every 3 weeks as monotherapy
Number of subjects: 113
Study 33355238 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-4166 with pembrolizumab 200 mg i.v. every 3 weeks for ≤35 doses
Number of subjects: 113
Study 33355238 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 113
Study 33355273 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOACs) - dabigatran, rivaroxaban, apixaban
Number of subjects: 256546
Study 33355273 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 256546
Study 33355854 — intervention group
Group type: EXPERIMENTAL
Intervention: Turkish version of the Oxford Participation and Activities Questionnaire (Ox-PAQ)
Number of subjects: 290
Study 33355907 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO patients (n=101)
Number of subjects: 396
Study 33355907 — intervention group
Group type: COMPARATOR
Intervention: Non-ACO patients (n=295)
Number of subjects: 396
Study 33355907 — intervention group
Group type: EXPERIMENTAL
Intervention: ACO patients
Number of subjects: 396
Study 33355914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg (DTG)-based regimen
Number of subjects: 0
Study 33355914 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Efavirenz 400 mg (EFV400)-based regimen
Number of subjects: 0
Study 33356015 — intervention group
Group type: EXPERIMENTAL
Intervention: Afternoon exercise training (3.00-6.00 p.m., N = 20)
Number of subjects: 32
Study 33356015 — intervention group
Group type: COMPARATOR
Intervention: Morning exercise training (8.00-10.00 a.m., N = 12)
Number of subjects: 32
Study 33356019 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral 100-mg glasdegib dose under fasted conditions
Number of subjects: 0
Study 33356019 — intervention group
Group type: COMPARATOR
Intervention: Matched controls with normal hepatic function
Number of subjects: 0
Study 33356355 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous myocardial infarction
Number of subjects: 0
Study 33356355 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33356383 — intervention group
Group type: EXPERIMENTAL
Intervention: Bashir Endovascular Catheter (BEC)
Number of subjects: 9
Study 33356392 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 13
Study 33356398 — intervention group
Group type: COMPARATOR
Intervention: Systolic BP <120 mm Hg
Number of subjects: 1738
Study 33356398 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP 120 to 140 mm Hg
Number of subjects: 1738
Study 33356398 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP 140 to 160 mm Hg
Number of subjects: 1738
Study 33356398 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP ≥160 mm Hg
Number of subjects: 1738
Study 33356406 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 4296
Study 33356406 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed high-rate detection and single-zone programming
Number of subjects: 4296
Study 33356665 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of POC culture
Number of subjects: 1545
Study 33356665 — intervention group
Group type: COMPARATOR
Intervention: No availability of POC culture
Number of subjects: 1545
Study 33357452 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunogenic chemotherapy combined with checkpoint blockade
Number of subjects: 0
Study 33357452 — intervention group
Group type: COMPARATOR
Intervention: Checkpoint blockade alone
Number of subjects: 0
Study 33357481 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33358103 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with aortic endoprosthesis
Number of subjects: 91
Study 33358103 — intervention group
Group type: COMPARATOR
Intervention: Deployment in zone 0-1
Number of subjects: 91
Study 33358103 — intervention group
Group type: COMPARATOR
Intervention: Branched or fenestrated endograft
Number of subjects: 91
Study 33358103 — intervention group
Group type: COMPARATOR
Intervention: Proximal endoprosthesis diameter ≥ 40 mm
Number of subjects: 91
Study 33358103 — intervention group
Group type: COMPARATOR
Intervention: Urgent procedure
Number of subjects: 91
Study 33358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone antagonists (spironolactone, eplerenone) added to ACE inhibitors (ACEi) or angiotensin II receptor blockers (ARBs)
Number of subjects: 0
Study 33358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal MR blockers
Number of subjects: 0
Study 33358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone added to treatment in patients with type 2 diabetes mellitus and CKD
Number of subjects: 0
Study 33358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium glucose type 2 cotransporter inhibitors (SGLT2i)
Number of subjects: 0
Study 33358451 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of ACEi or ARBs, SGLT2i, and aldosterone antagonist
Number of subjects: 0
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker testing for EGFR, ALK, ROS1, BRAF, KRAS, MET, TP53, RET, HER2, and PD-L1 expression
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for druggable EGFR mutations
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for druggable ALK alterations
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for KRAS alterations
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for TP53 alterations
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for EGFR alterations
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for PD-L1 expression
Number of subjects: 3717
Study 33358484 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing methods used
Number of subjects: 3717
Study 33358660 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33358713 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF) - 500 kcal fast day alternated with ad libitum intake feast day for 12 weeks
Number of subjects: 75
Study 33358716 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoids status (SCS)
Number of subjects: 103
Study 33358716 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma carotenoids
Number of subjects: 103
Study 33358716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary carotenoids
Number of subjects: 103
Study 33359234 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal liver tests on admission
Number of subjects: 1611
Study 33359404 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg
Number of subjects: 100
Study 33359404 — intervention group
Group type: COMPARATOR
Intervention: Standard second-line doublet chemotherapy plus a targeted agent
Number of subjects: 100
Study 33359443 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe recurrent wheeze (SRW)
Number of subjects: 338
Study 33359443 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma (SA)
Number of subjects: 338
Study 33360365 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-enhanced family-focused therapy (FFT) with a mobile app (12 sessions in 18 weeks)
Number of subjects: 22
Study 33360855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1567
Study 33361170 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised breast cancer screening intervention
Number of subjects: 385
Study 33361275 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual simulation with Sim&Size software
Number of subjects: 186
Study 33361275 — intervention group
Group type: COMPARATOR
Intervention: Conventional sizing
Number of subjects: 186
Study 33361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (dosage not specified) as prophylaxis or treatment
Number of subjects: 33
Study 33361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (dosage not specified)
Number of subjects: 33
Study 33361303 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP) administered in standard 3-day courses at 4- to 8-week intervals from the second trimester until delivery.
Number of subjects: 467
Study 33361353 — intervention group
Group type: EXPERIMENTAL
Intervention: NYHA I
Number of subjects: 188
Study 33362277 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-CABG
Number of subjects: 180
Study 33362277 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 180
Study 33362277 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 180
Study 33362485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine treatment for AUD, specific dosage and duration not mentioned.
Number of subjects: 0
Study 33362485 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33362497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 33362497 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham stimulation)
Number of subjects: 0
Study 33362687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0
Study 33362687 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Number of subjects: 0
Study 33362687 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 33362722 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab and nivolumab
Number of subjects: 0
Study 33362722 — intervention group
Group type: COMPARATOR
Intervention: Anti-PD-1 (pembrolizumab)
Number of subjects: 0
Study 33362722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study 33362883 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools implementing the adapted life orientation curriculum with scripted lesson plans
Number of subjects: 0
Study 33362883 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 0
Study 33362896 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 33363071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 63
Study 33363071 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and Adalimumab (ADA)
Number of subjects: 63
Study 33363071 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (siblings of JIA patients)
Number of subjects: 63
Study 33363453 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote and wireless programming system for SCS devices
Number of subjects: 16
Study 33364332 — intervention group
Group type: EXPERIMENTAL
Intervention: Common OSA screening tools
Number of subjects: 0
Study 33364733 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method (CAM)
Number of subjects: 60
Study 33364733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing Delirium Screening Scale (nu-DESC)
Number of subjects: 60
Study 33364840 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance olaparib
Number of subjects: 0
Study 33364840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33365012 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and diet interventions
Number of subjects: 24
Study 33365220 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent Ethyl (IPE, Vascepa®)
Number of subjects: 1
Study 33365325 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein-lower glycemic index diet (HPLG)
Number of subjects: 0
Study 33365325 — intervention group
Group type: COMPARATOR
Intervention: Conventional moderate protein-moderate glycemic index diet (MPMG)
Number of subjects: 0
Study 33367114 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE plus usual HCBS
Number of subjects: 0
Study 33367114 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 33367731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (R406)
Number of subjects: 0
Study 33367735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus crispatus or Lactobacillus gasseri dominance in black women (n=12, 27%)
Number of subjects: 44
Study 33367735 — intervention group
Group type: COMPARATOR
Intervention: Vaginal microbial communities
Number of subjects: 44
Study 33367811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) variability measures (coefficient of variation (CV) and average real variability (ARV)) in ACCORD and VADT.
Number of subjects: 12042
Study 33367811 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) variability measures (CV and ARV) in both trials.
Number of subjects: 12042
Study 33367837 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study 33367918 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2-c1 (S2/cre5/S15domV/rec1/hifi3)
Number of subjects: 30
Study 33367918 — intervention group
Group type: EXPERIMENTAL
Intervention: nOPV2-c2 (S2/S15domV/CpG40)
Number of subjects: 30
Study 33367975 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir (DRV/r)
Number of subjects: 46
Study 33368056 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using high-definition white-light (HDWL) images
Number of subjects: 60
Study 33368056 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided diagnosis system (CADx) using blue-light imaging (BLI) images
Number of subjects: 60